Immune checkpoint molecules signal regulatory protein alpha in the development of hepatocellular carcinoma

Table 1 Clinical trials related to signal regulatory protein alpha

Tumor	Interventions	Phase	Number enrolled	NCT number	Study start	Sponsor/collaborators
Lymphoma	Ontorpacept	II (recruiting)	41	NCT05507541	April 19, 2023	Mayo Clinic
Advanced solid tumor; breast cancer	Drug: DS-1103a; Drug: T-DXd	I (recruiting)	78	NCT05765851	May 30, 2023	Daiichi Sankyo
Colorectal cancer	Drug: Evorpacept (ALX148); Drug: Cetuximab; Drug: Pembrolizumab	II (active, not recruiting)	80	NCT05167409	July 28, 2022	University of Colorado, Denver, CO, United States
Leukemia, myeloid, acute; myelodysplastic syndromes	Drug: CC-95251; Drug: Azacitidine; Drug: Venetoclax	I (completed)	56	NCT05168202	January 19, 2022	Bristol-Myers Squibb
Solid tumors; mycosis fungoides; melanoma	TTI-621 + PD-1/PD-L1 Inhibitor	I (terminated)	56	NCT02890368	September 2016	Pfizer
Lymphoma	Drug: CD47 Antagonist ALX148; Drug: Lenalidomide; Biological: Rituximab	I/II (recruiting)	60	NCT05025800	October 13, 2021	M.D. Anderson Cancer Center
Hepatocellular carcinoma	SIRPα Ab	Complete	30	NCT02868255	January 13, 2016	Nantes University Hospital
Acute myeloid leukemia	Drug: Evorpacept; Drug: Venetoclax; Drug: Azacitidine	I (terminated)	14	NCT04755244	May 5, 2021	ALX Oncology Inc.
Higher risk myelodysplastic syndromes	Drug: Evorpacept; Drug: Azacitidine	I/II (active, not recruiting)	65	NCT04417517	October 2, 2020	ALX Oncology Inc.
Multiple myeloma	Drug: Elranatamab; Drug: Carfilzomib; Drug: Maplirpacept	I (recruiting)	90	NCT05675449	December 14, 2022	Pfizer
Brain cancer	Drug: Magrolimab	I (completed)	13	NCT05169944	April 22, 2022	University of California, San Francisco, CA, United States
Multiple myeloma	Drug: TTI-622; Drug: Daratumumab Hyaluronidase-fihj	I (active, not recruiting)	7	NCT05139225	October 28, 2021	Memorial Sloan Kettering Cancer Center
Bladder cancer; urothelial carcinoma	Drug: Evorpacept; Drug: Enfortumab Vedotin	I (recruiting)	30	NCT05524545	November 2, 2022	ALX Oncology Inc.
Advanced solid cancers; hematologic cancers	Drug: SRF231	I (completed)	148	NCT03512340	March 13, 2018	Surface Oncology
Head and neck squamous cell carcinoma	Drug: BI 765063; Drug: Ezabenlimab	I (active, not recruiting)	48	NCT05249426	April 12, 2022	Boehringer Ingelheim
Breast cancer	Drug: ALX148; Drug: Fam-Trastuzumab Deruxtecan-Nxki; Drug: Zanidatamab	I (recruiting)	54	NCT05868226	December 22, 2022	QuantumLeap Healthcare Collaborative

PD-L1: Programmed death ligand 1; PD-1: Programmed cell death 1.